Genesys Biologics Profile
Key Indicators
- Authorised Capital ₹ 3.50 Cr
as on 27-06-2024
- Paid Up Capital ₹ 2.33 Cr
as on 27-06-2024
- Company Age 10 Year, 1 Month
- Last Filing with ROC 31 Mar 2023
- Open Charges ₹ 69.50 Cr
as on 27-06-2024
- Satisfied Charges ₹ 50.28 Cr
as on 27-06-2024
About Genesys Biologics
The Company is engaged in the Life Sciences Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 3.50 Cr and a paid-up capital of Rs 2.33 Cr.
The company currently has active open charges totaling ₹69.50 Cr. The company has closed loans amounting to ₹50.28 Cr, as per Ministry of Corporate Affairs (MCA) records.
Venkata Dasari, Tulasiramu Chatadi, Yelma Reddy, and Two other members serve as directors at the Company.
- CIN/LLPIN
U24232TG2014PTC096432
- Company No.
096432
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
18 Nov 2014
- Date of AGM
30 Sep 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Hyderabad
Industry
Company Details
- Location
Hyderabad, Telangana, India
- Telephone
- Email Address
- Website
- Social Media-
Who are the key members and board of directors at Genesys Biologics?
Board Members(5)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Venkata Dasari  | Director | 20-Aug-2015 | Current |
| Tulasiramu Chatadi | Director | 20-Aug-2015 | Current |
| Yelma Reddy | Director | 05-Feb-2015 | Current |
Kondrella Roopesh  | Director | 06-Feb-2015 | Current |
| Vamshider Rao | Director | 18-Nov-2014 | Current |
Financial Performance and Corporate Structure Insights of Genesys Biologics.
Genesys Biologics Private Limited, for the financial year ended 2023, experienced no change in revenue, with a 0% increase. The company also saw a no change in profitability, with a 0% increase in profit. The company's net worth witnessed no change by increase of 0%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue | |||||||
| Revenue from Operations | |||||||
| Total Assets | |||||||
| Profit or Loss | |||||||
| Net Worth | |||||||
| EBITDA |
What is the Ownership and Shareholding Structure of Genesys Biologics?
In 2023, Genesys Biologics had a public holding of 42.79%. The company had 1 Associate company. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Rygen Biopharma Private LimitedActive 4 years 2 daysVenkata Dasari and Tulasiramu Chatadi are mutual person
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
State Bank Of India Creation Date: 03 Aug 2018 | ₹11.00 Cr | Open |
State Bank Of India Creation Date: 21 Jul 2017 | ₹58.50 Cr | Open |
Others Creation Date: 07 Sep 2017 | ₹2.25 M | Satisfied |
How Many Employees Work at Genesys Biologics?
Genesys Biologics has a workforce of 259 employees as of Apr 07, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Genesys Biologics, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Genesys Biologics's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
